Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Q1 Revenues Fall 14 Percent; Company Will Remain on Nasdaq, but Plans Management Changes

NEW YORK, June 22 (GenomeWeb News) - Orchid Cellmark said today that its first-quarter revenues dropped 14 percent as net losses ballooned to $6.6 million from $1.7 million in the year-ago period. 


The company's earnings reports for the quarter ended March 31 and the full year 2005 were delayed, resulting in two delisting notices from Nasdaq. Orchid Cellmark said today that it will continue to be listed on the Nasdaq exchange despite that delay.


"Our first quarter results were, to say the least, extremely disappointing," said Thomas Bologna, Orchid president and CEO, in a statement. "The company's poor results reflect operational weaknesses in the company that we are now addressing aggressively. Restructuring, including senior management changes at the company's Princeton office, and other remedial actions are underway. However, we expect operating challenges will continue for the remainder of 2006," he said.


Orchid's revenues declined to $12.6 million in the first quarter of 2006, from $14.7 million during the first quarter of 2005. the company attributed the decline to a reduction in price and volume of US forensic cases billed, a drop in the price of US government paternity testing services, and lower demand for its UK crime and agricultural testing services.


Service revenue was adversely affected by currency translation from Britain to the United States, the company said.


Orchid reported a net loss for the first quarter of 2006 of $6.6 million, or $0.27 per share, compared to $1.7 million, or $0.07 per share, for the first quarter of 2005.


Orchid spent $397,000 on R&D in the first quarter of 2006, compared to $278,000 in the first quarter of 2005.


The company had cash and equivalents of $19.8 million as of March 31.


The Nasdaq Listing Qualifications Panel granted Orchid's request to remain listed on the exchange despite having missed the filing deadline for its 2005 full-year earnings report, as well as failing to file its earnings report for the quarter ended March 31 on time.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.